Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Journal of Biopharmaceutical Statistics
|
December 23, 2021
Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study
Xi Wang, Leah Suttner, Thomas Jemielita, et al.
BMC Health Services Research
|
March 8, 2020
Testing patient-informed approaches for visually depicting the hemoglobin A1c value to patients with poorly controlled diabetes: a randomized, controlled trial
Anjali Gopalan, Leah Suttner, Andrea B Troxel, et al.
Contemporary Clinical Trials
|
August 28, 2020
Independent drug action and its statistical implications for development of combination therapies
Cong Chen, Fang Liu, Yixin Ren, et al.
Trials
|
July 18, 2016
No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals
Nicole B Gabler, Naihua Duan, Eli Raneses, et al.
Clinical Colorectal Cancer
|
June 28, 2024
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer
Alberto Bessudo, Abdul Mustajeeb Haseeb, James A Reeves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2022
Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Journal for Immunotherapy of Cancer
|
January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
Julie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Journal of Biopharmaceutical Statistics
|
December 23, 2021
Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study
Xi Wang, Leah Suttner, Thomas Jemielita, et al.
BMC Health Services Research
|
March 8, 2020
Testing patient-informed approaches for visually depicting the hemoglobin A1c value to patients with poorly controlled diabetes: a randomized, controlled trial
Anjali Gopalan, Leah Suttner, Andrea B Troxel, et al.
Contemporary Clinical Trials
|
August 28, 2020
Independent drug action and its statistical implications for development of combination therapies
Cong Chen, Fang Liu, Yixin Ren, et al.
Trials
|
July 18, 2016
No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals
Nicole B Gabler, Naihua Duan, Eli Raneses, et al.
Clinical Colorectal Cancer
|
June 28, 2024
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer
Alberto Bessudo, Abdul Mustajeeb Haseeb, James A Reeves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 15, 2022
Correction: First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2021
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Correction: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Lillian L Siu, Ding Wang, John Hilton, et al.
Journal for Immunotherapy of Cancer
|
January 19, 2024
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
Vicky Makker, Matthew H Taylor, Carol Aghajanian, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
Julie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Page
of 1